The Bi-Specific MAbS by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Bi-Specific MAbS Market:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report
According to The Business Research Company’s Bi-Specific MAbS, The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding and government initiatives.
The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population and an increase in the prevalence of chronic diseases. Major trends in the forecast period include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships.
The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp
The bi-specific mabs market covered in this report is segmented –
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users
Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives, such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. A strategic collaboration is a cooperative partnership between two or more organizations to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company and MacroGenics, a US-based biopharmaceutical company, entered into an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics' DART platform, along with two other bispecific research programs. The collaboration grants Gilead an exclusive option to license MGD024, which has the potential to treat various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) and allow intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS .
The bi-specific mabs market report table of contents includes:
- Executive Summary
- Biotechnology Services MarketCharacteristics
- Biotechnology Services MarketTrends And Strategies
- Biotechnology Services Market- Macro Economic Scenario
- Global Biotechnology Services MarketSize and Growth
.
.
.
- Global Biotechnology Services MarketCompetitive Benchmarking
- Global Biotechnology Services MarketCompetitive Dashboard
- Key Mergers And Acquisitions In Biotechnology Services Market
- Biotechnology Services MarketFuture Outlook and Potential Analysis
- Appendix
Top Major Players :
- Hoffmann-La Roche AG
- Amgen Inc.
- Johnson & Johnson
- Innovent Biologics
- Sino Biological Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
May 07, 2019: Global Bi-Specific Antibodies Market is estimated to grow at a substantial CAGR in the forecast period as the scope, product types, and its applications are increasing across the globe.
On the other hand, there are factors that may hamper the growth of the market including regulatory trials, and production hurdles in bi-specific antibodies growth.Download sample Copy of This Report at: https://www.radiantinsights.com/research/global-bi-specific-antibodies-market-forecast-to-2022/request-sample Bi-Specific Antibodies Market may be explored by key therapeutic areas, mechanisms of action, and geography.
Bi-Specific Antibodies Market may be explored by key therapeutic areas as autoimmune disorders, oncology, eye disorders, inflammatory disorders, and others.
The factors that could be attributed to the growth include increasing occurrence of diseases such as lung cancer, prostate cancer, breast cancer, and cervical cancer, and rise in the awareness levels toward health.Browse Full Report With TOC @ https://www.radiantinsights.com/research/global-bi-specific-antibodies-market-forecast-to-2022 The key players contributing to the robust growth of the Bi-Specific Antibodies Market comprise Bayer AG, Amgen, Inc., ImmunGene, Inc., Dow Pharmaceutical Solutions, Merck & Co., Inc., Immunocore Limited, Novartis AG, F. Hoffmann-La Roche AG, and Pfizer, Inc.
These antibodies are of particular importance for patients who experience recurrence or resistance to drugs.According to the RNCOS report entitled “Global Bi-Specific Antibodies Market Forecast to 2022”, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period.
Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs.Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report.
ResearchForetell has published a report entitled Global MABS Market Research Report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances and various strategies implemented by the main current market players.
The report is based on a collective analysis of data, which is obtained through primary and secondary research.
It provides a systematic approach to the current and prospective scenario of this market.Request sample copy of this report at https://www.researchforetell.com/reports/42755/mabs-market---global-outlook-and-forecast-2021-2027/requestThis report contains market size and forecasts of MABS in global, including the following market information:Global MABS Market Revenue, 2016-2021, 2022-2027, ($ millions)Global MABS Market Sales, 2016-2021, 2022-2027, (MT)Global top five MABS companies in 2020 (%)The global MABS market was valued at 436.3 million in 2020 and is projected to reach US$ 507 million by 2027, at a CAGR of 3.8% during the forecast period.MARKET MONITOR GLOBAL, INC (MMG) has surveyed the MABS manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.Total Market by Segment:Global MABS Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (MT)Global MABS Market Segment Percentages, By Type, 2020 (%) General Purpose Grade High Impact Grade High Rigidity Grade OtherGlobal MABS Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (MT)Global MABS Market Segment Percentages, By Application, 2020 (%) Appliance Industry 3C Products Toys Medical Industry OtherGlobal MABS Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (MT)Global MABS Market Segment Percentages, By Region and Country, 2020 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & AfricaCompetitor AnalysisThe report also provides analysis of leading market participants including:Key companies MABS revenues in global market, 2016-2021 (Estimated), ($ millions)Key companies MABS revenues share in global market, 2020 (%)Key companies MABS sales in global market, 2016-2021 (Estimated), (MT)Key companies MABS sales share in global market, 2020 (%)Further, the report presents profiles of competitors in the market, key players include: Toray LG Chem Chi Mei LOTTE Advanced Materials Styrolution Techno-UMG Denka Formosa Chemicals & Fibre NIPPON AThe report collects relevant data in a method that allows readers to understand individual elements and their interactions in the current market scenario.
It focuses on the necessary modifications for new and existing businesses to evolve and adapt to future trends in this market.
In addition, it helps the reader to identify salient features of the Global MABS Market Research Report 2021 and provides sufficient statistical data to understand its operation.
It also examines possible deficiencies along with the problems encountered by new and predominant companies.To conclude, this MABS Market report covers all the necessary financial, economic and social factors relevant to the industry enhancing the reader with the information required to make an informed decision.The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The Global MABS Market Report is prepared to club all the essential market details such as market size, share, value, growth, restraints, challenges, and opportunities during the study period of 2020-2025.
The data presented in this report has been gathered on the basis of historical data, primary interviews and expert's estimation of future trends.
The report also covers regional assessment which has been conducted globally.
The detailed content of the market study ensures intellectual insights given a better understanding of the untapped opportunities in the market.MABS is a copolymer of methyl methacrylate, acrylonitrile, butadiene, styrene, and it has ordinary ABS resin’s mechanical properties, but higher impact toughness and transparency than ABS.MMA and ABS are the main raw materials.
Most companies produce MABS by themselves.
MABS are often applied in appliance industry, automobile industry, optoelectronics industry, of which appliance industry occupy the largest share.The world MABS production will increase at a growth rate of about 6.10%.
